(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 2 251 014 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
08.01.2014 Bulletin 2014/02

(45) Date of publication and mention of the grant of the patent:
20.11.2013 Bulletin 2013/47

(21) Application number: **09718009.5**

(22) Date of filing: **04.03.2009**

(51) Int Cl.:
A61K 31/704 *(2006.01)* ***A61K 31/282*** *(2006.01)*
A61K 31/337 *(2006.01)* ***A61K 31/7072*** *(2006.01)*
A61K 33/24 *(2006.01)* ***A61K 45/06*** *(2006.01)*
A61P 35/00 *(2006.01)* ***A61P 43/00*** *(2006.01)*
C07J 9/00 *(2006.01)*

(86) International application number:
PCT/JP2009/000985

(87) International publication number:
WO 2009/110235 (11.09.2009 Gazette 2009/37)

(54) COMBINATIONS OF AN ANTI-CANCER AGENT AND A CHOLESTANOL DERIVATIVE

KOMBINATIONEN AUS EINEM ANTIKREBSMITTEL UND EINEM CHOLESTANOLDERIVAT

COMBINAISONS CONTENANT UN AGENT ANTI-CANCER ET UN DERIVÉ DU CHOLESTANOL

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: **05.03.2008 JP 2008055284**

(43) Date of publication of application:
17.11.2010 Bulletin 2010/46

(73) Proprietors:
- **Otsuka Pharmaceutical Co., Ltd.**
  Tokyo 101-8535 (JP)
- **National University Corporation**
  Gunma University
  Maebashi-shi
  Gunma 371-8510 (JP)

(72) Inventors:
- **YAZAWA, Shin**
  Osaka-shi
  Osaka 541-0045 (JP)
- **NISHIMURA, Toyo**
  Osaka-shi
  Osaka 541-0045 (JP)
- **ASAO, Takayuki**
  Maebashi-shi
  Gunma 371-0031 (JP)

(74) Representative: **Hartz, Nikolai**
Wächtershäuser & Hartz
Patentanwaltspartnerschaft
Ottostrasse 4
80333 München (DE)

(56) References cited:
WO-A1-2005/007172
WO-A1-2007/026869
WO-A2-2005/118071
JP-A- 11 060 592
JP-A- 2000 191 685

- **AHMAD FARIED ET AL: "Chemically synthesized sugar-cholestanols possess a preferential anticancer activity involving promising therapeutic potential against human esophageal cancer", CANCER SCIENCE, vol. 98, no. 9, 1 September 2007 (2007-09-01), pages 1358-1367, XP55024322, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2007.00563.x**

Remarks:
The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 251 014 B8